Catalog No.
PAJ85301
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Belimumab
Specificity
The product is specific for Belimumab. This antibody serves as an excellent positive control for Belimumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Antigen affinity purification.
Accession
CAS: 356547-88-1
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2-3 weeks at 2-8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Alternative Names
Rabbit polyclonal to REGN-10987.
Background
Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE).
Rare case of systemic lupus with manifestation of FS Jaccoud arthropathy: a case report and literature review., PMID:40461984
Alternation of anti-NMDA receptor subunit GluN2 antibody in a patient with SLE who promptly developed anxiety after belimumab., PMID:40455606
Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years., PMID:40442811
Chilblains With Tumid Lupus Features in a Patient With Sjögren's Syndrome: A Case Report., PMID:40385803
Differences in dynamics of specific anti-nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus., PMID:40356198
Efficacy and safety of belimumab versus rituximab for refractory immune thrombocytopenia in patients with connective tissue disease., PMID:40355343
Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials., PMID:40346603
Efficacy and Safety of Biologics and Immunosuppressants in Maintenance Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Network Meta-Analysis., PMID:40325583
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis., PMID:40322925
Role of B-Cell Inhibition in Autoimmune Hepatitis: Lessons Learnt From Systemic Lupus Erythematosus., PMID:40276396
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria., PMID:40274305
Role of belimumab in recurrent spontaneous abortions amongst patients with lymphocyte dysfunction: a retrospective case-control study., PMID:40259254
Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumab., PMID:40244828
Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment., PMID:40242921
Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study., PMID:40172681
[Lupus nephritis - does a lot help a lot?]., PMID:40164100
Integrative miRNA-mRNA profiling uncovers mechanisms of belimumab action in systemic lupus erythematosus., PMID:40160819
Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus., PMID:40081913
Belimumab patient profile in Spain: evolution during the last decade and future directions., PMID:40077897
Systemic lupus erythematosus: one year in review 2025., PMID:40072872
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases., PMID:40058377
A focused report on IFN-1 targeted therapies for lupus erythematosus., PMID:40047795
Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting., PMID:40037576
A Review of Therapeutics for the Treatment of Lupus., PMID:40016631
Treatment of thrombotic microangiopathy associated with systemic lupus erythematosus with low-dose rituximab as an induction agent and belimumab as a maintenance agent., PMID:40001033
Renal recovery from membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated glomerulonephritis with belimumab., PMID:39995263
A Case Report of Severe Systemic Lupus Erythematosus with Anti-centromere Antibody., PMID:39993749
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab., PMID:39985454
Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase., PMID:39975549
Real-World Effectiveness of Intravenous Belimumab on Clinical Outcomes in Patients With Systemic Lupus Erythematosus in Saudi Arabia: The OBSErve Observational Study., PMID:39973976
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review., PMID:39958566
Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches., PMID:39940698
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report., PMID:39939125
Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis., PMID:39935484
Impact of belimumab on glucocorticoid intake in newly diagnosed systemic lupus erythematosus., PMID:39924363
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways., PMID:39919899
A case of posterior and reversible encephalopathy syndrome in a patient previously undiagnosed with lupus nephritis., PMID:39918729
Lupus Enteritis as the Early Manifestation of Systemic Lupus Erythematosus Successfully Managed With Belimumab: A Case Report., PMID:39906430
Ten tips in lupus nephritis management., PMID:39872638
Effectiveness of Belimumab for Glucocorticoid Discontinuation in Juvenile-Onset Lupus Nephritis., PMID:39872261
[The clinical significance of resolvin D1 in patients with systemic lupus erythematosus treated with Belimumab]., PMID:39865019
CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy., PMID:39832454
Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study., PMID:39827426
Novel therapies in SLE treatment: A literature review., PMID:39817571
Inhibition of B-cell activating factor activity using active compounds from Physalis angulata in the mechanism of nephrotic syndrome improvement: A computational approach., PMID:39816050
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis., PMID:39793999
The beneficial effect of adding belimumab in severe and refractory IgA nephropathy: a case report., PMID:39779507
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study., PMID:39762087
Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review., PMID:39759646
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups., PMID:39706676
For research use only. Not for human or drug use.
